Sodium-Glucose Cotransporter 2 Inhibitors Improve Body Composition by Increasing the Skeletal Muscle Mass/Fat Mass Ratio in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study

Nutrients, Journal Year: 2024, Volume and Issue: 16(22), P. 3841 - 3841

Published: Nov. 9, 2024

Sodium-glucose cotransporter 2 inhibitors (SGLT2is) induce body weight loss, but their effect on skeletal muscle mass (SMM) and strength needs to be better elucidated.

Language: Английский

---

Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(7), P. 3832 - 3832

Published: March 29, 2024

Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are incretins that regulate postprandial glucose regulation, stimulating insulin secretion from pancreatic β-cells in response to food ingestion. Modified GLP-1 receptor agonists (GLP-1RAs) being administered for the treatment of obesity type 2 diabetes mellitus (T2DM). Strongly related those disorders, metabolic dysfunction-associated steatotic liver disease (MASLD), especially its aggressive form, defined as steatohepatitis (MASH), is a major healthcare burden associated with high morbidity extrahepatic complications. GLP-1RAs have been explored MASH patients evident improvement dysfunction enzymes, glycemic control, weight loss. Importantly, combination GIP and/or glucagon RAs may be even more effective via synergistic mechanisms amelioration metabolic, biochemical, histological parameters MASLD but also has beneficial impact on MASLD-related In this current review, we aim provide an overview incretins’ physiology, action, signaling. Furthermore, insight into key pathophysiological through which they aspects, well analyze clinical data human interventional studies. Finally, discuss challenges future perspectives pertinent growing area research medicine.

Language: Английский

---

Effect of Semaglutide on Body Composition, Physical Function, and Biomarkers of Aging in Older, Overweight Adults with Insulin Resistance: Protocol for an Open-labeled Randomized Controlled Trial (Preprint)

JMIR Research Protocols, Journal Year: 2024, Volume and Issue: 13, P. e62667 - e62667

Published: July 11, 2024

Older adults with type 2 diabetes mellitus (T2DM) or prediabetes are at increased risk of adverse changes in body composition, physical function, and aging-related biomarkers compared to those normal glucose tolerance. Semaglutide is a glucagon-like peptide 1 receptor agonist that has been approved for T2DM chronic weight management. Although semaglutide effective loss management, its effects on lean mass, aging understudied older adults.

Language: Английский

---

Ocular adverse events associated with GLP-1 receptor agonists: a Real-World Study Based on the FAERS database and network pharmacology

Expert Opinion on Drug Safety, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 19, 2024

This study evaluates the risk of ocular adverse events (AEs) associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) by analyzing data from FDA Adverse Event Reporting System (FAERS) and employing network pharmacology methods.

Language: Английский

---

Treatment of hypothalamic obesity with GLP-1 analogs

Journal of the Endocrine Society, Journal Year: 2024, Volume and Issue: 9(1)

Published: Nov. 14, 2024

Abstract Introduction Congenital and acquired damage to hypothalamic nuclei or neuronal circuits controlling satiety energy expenditure results in obesity (HO). To date, successful weight loss has only been achieved a limited number of affected patients across multiple drug trials. Glucagon-like peptide-1 (GLP-1) acts via central pathways that are independent from the hypothalamus induce satiety. GLP-1 receptor agonists (GLP-1RAs) may provide an alternative approach treating HO. Methods We performed comprehensive search Medline, Google Scholar, clinical trials registries (ClinicalTrials.gov; clinicaltrialsregister.eur). This nonsystematic literature review was conducted identify scientific papers published January 2005 February 2024 using Pubmed Embase databases. Key words used were GLP-1, GLP-1RA, obesity, suprasellar tumor, craniopharyngioma. Results Our identified 7 case studies, 5 series, 2 relating use GLP-1RAs All studies demonstrated improved metabolic function. In contrast, series variable, with some showing no others demonstrating moderate significant parameters. ECHO trial, nearly half subjects randomized weekly exenatide showed reduced body mass index (BMI). Paradoxically, BMI reduction greater more extensive injuries. Conclusion potentially offer new There is need stratify who likely respond. Further controlled required determine their efficacy either isolation combined other therapies.

Language: Английский

---